Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment

Kenneth G. Saag, Andrew Whelton, Michael A. Becker, Patricia MacDonald, Barbara Hunt, Lhanoo Gunawardhana

Research output: Contribution to journalArticle

Abstract

Objective: Renal impairment is a risk factor for gout and a barrier to optimal gout management. We undertook this exploratory study to obtain data that have been heretofore limited regarding the safety and efficacy of febuxostat in patients with moderate-to-severe renal impairment (estimated glomerular filtration rate [GFR] 15–50 ml/minute/1.73 m2). Methods: Ninety-six gout patients with moderate-to-severe renal impairment were enrolled in a 12-month multicenter, randomized, double-blind, placebo-controlled study. Patients were randomly assigned at a 1:1:1 ratio to receive 30 mg febuxostat twice daily, 40/80 mg febuxostat once daily, or placebo. The primary efficacy end point was the change in serum creatinine (Cr) level from baseline to month 12. Secondary end points included the change in estimated GFR from baseline to month 12 and the proportion of patients with a serum uric acid (UA) level of

Original languageEnglish (US)
Pages (from-to)2035-2043
Number of pages9
JournalArthritis and Rheumatology
Volume68
Issue number8
DOIs
StatePublished - Aug 1 2016

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology

Fingerprint Dive into the research topics of 'Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment'. Together they form a unique fingerprint.

  • Cite this

    Saag, K. G., Whelton, A., Becker, M. A., MacDonald, P., Hunt, B., & Gunawardhana, L. (2016). Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis and Rheumatology, 68(8), 2035-2043. https://doi.org/10.1002/art.39654